PVI
HZNP

Pura Vida Investments’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Pura Vida Investments’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-109,000
Closed -$3.95M – 142
2019
Q4 		$3.95M Buy
+109,000
New +$3.34M 0.35% 68
2016
Q4 		– Sell
-50,000
Closed -$907K – 108
2016
Q3 		$907K Buy
+50,000
New +$977K 0.28% 71

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Pura Vida Investments's HZNP Position: Q1 2023 in Review

Pura Vida Investments sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2023, closing a stake of 12,900 shares — an estimated $1.47M sold.

Pura Vida Investments first reported a position in HZNP in Q3 2016 and held it in 8 quarters. The position peaked at $6.99M in Q3 2020. 553 funds tracked by Wall St. Rank hold HZNP as of Q1 2023.

  • Pura Vida Investments reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2023 after selling out during the quarter.
  • Pura Vida Investments sold 12,900 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2023, an estimated $1.47M.
  • Pura Vida Investments first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2016 and held it in 8 quarters.
  • Pura Vida Investments's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $6.99M in Q3 2020.
  • 553 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2023.

Based on Pura Vida Investments's 13F filing for Q1 2023, filed 15 May 2023.